Project Grant K01CA297135
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$166K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The Johns Hopkins University was awarded a $431,561 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research aimed at elucidating the role of the HMGA1 chromatin regulator in pancreatic ductal adenocarcinoma (PDAC) progression and the tumor microenvironment (TME). The research project seeks to precisely define HMGA1-dependent mechanisms in PDAC tumor progression using mouse models and primary human tumors, as well as...
This federal Project Grant award of $436,431 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to target metabolic crosstalk in pancreatic ductal adenocarcinoma (PDA). The University of California, Irvine is the prime awardee, conducting fundamental investigations into mechanisms that maintain cancer cell heterogeneity and metabolic symbiosis in PDA tumors. The research aims to identify oncogenic and stress pathways that can be targeted to...
The National Cancer Institute (NCI) awarded a $269,280 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Translational Genomics Research Institute (TGen), a non-profit biomedical research organization, to conduct preclinical research on targeting cellular senescence in pancreatic ductal adenocarcinoma (PDAC). The grant aims to determine the biological effects of a senescent cell-targeted antibody, SIWA318, and evaluate its ability to improve the efficacy of standard-of-care...
This Project Grant award of $145,000 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research on the role of the JMJD4 enzyme in pancreatic cancer. The overarching goal is to advance the mechanistic understanding of how JMJD4 functions and its potential as a novel target for pancreatic cancer treatment.
Specifically, the research will (1) determine the role of JMJD4 in pancreatic cancer cells, and (2) reveal how JMJD4 acts at the...
This $667,118 five-year Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research by the University of California, San Francisco (UCSF) to identify and target key lysosomal proteins that enable the growth and metastasis of pancreatic ductal adenocarcinoma (PDAC), an incurable form of pancreatic cancer.
The primary objectives are to: 1) explore the role of the lysosomal hydrolase PLBD1 in supporting PDAC cell metabolism by removing...
This $590,625 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop a novel therapeutic strategy targeting mutant p53, a key driver of tumor progression and therapy resistance in more than half of human cancers. The principal investigator at the University of California, Davis (UC Davis) will:
Determine how mutant p53 expression is regulated by the CDK4/6-RBM38-eIF4G axis and the role of mutant...
The federal Project Grant award of $571,350.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding the "METABOLIC INTERVENTIONS TO HALT PANCREATIC CANCER" research project at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, CA. The award, with a performance period from November 1, 2024 to October 31, 2027, will support the institute's biomedical research efforts focused on developing innovative...
This $125,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to investigate the role of cellular metabolism in regulating precancerous stages of pancreatic cancer development.
The key products and services to be delivered through this 2-year grant include: 1) Mechanistic studies on how the metabolic enzyme ME1 contributes to acinar-to-ductal metaplasia (ADM) and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $148,568.00 in funding to the Fred Hutchinson Cancer Center in Seattle, WA to support research exploring the molecular mechanisms controlling CDK7 inhibitor sensitivity in pancreatic ductal adenocarcinoma (PDA). The proposed research under this 1.5-year award aims to: 1) identify how the tumor suppressor SIRT6 affects ATF4 stability in PDA, 2) characterize the in vivo efficacy...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sanford Burnham Prebys Medical Discovery Institute to investigate macropinocytosis as a metabolic adaptation in pancreatic cancer cells treated with the glutamine mimetic 6-diazo-5-oxo-L-norleucine (DON). The $561,077 award, spanning July 2024 to June 2029, aims to elucidate the role of the WNK4 kinase in regulating macropinocytosis and...